AstraZeneca Patent-Cliff Exposure & CMS Drug Spending Portfolio
AstraZeneca (Wilmington, DE): 46 reconciled FDA prescription therapies (40.6% 2025 to 2030 cliff risk), $17.59B 2024 CMS Part D & Medicaid spend, and 26 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Wilmington, DE |
| Reconciled FDA Portfolio Therapies | 46 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 40.6% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $17.59B |
| 2024 Medicare Part D Spend | $14.31B |
| 2024 Medicaid Spend | $3.29B |
| California HCAI SB 17 Filings | 26 WAC filings (max 24.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.